Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal ...

Novo Nordisk aims to revolutionize diabetes care with Awiqli, a potential once-weekly insulin, resubmitted for FDA approval ...

SAN DIEGO, September 29, 2025--t:slim X2 insulin pump with Control-IQ+ technology now cleared for use with Lyumjev ...

Approximately 9.5 million people globally live with type 1 diabetes, a chronic autoimmune disease where T cells from the body ...

If approved, Awiqli would become the first once-weekly basal insulin available in the United States for adults with Type 2 ...

Dr Shivani Misra is a clinical associate professor and honorary consultant in diabetes at Imperial College London ...

Novo Nordisk’s weekly injection for type 2 diabetes, Ozempic, is set to launch in India. Here’s how it works, its benefits, ...

Ozempic has been approved in India for type 2 diabetes. The blockbuster drug by Danish drugmaker Novo Nordisk has taken the ...

Chronic diseases are no joke. Anyone who has ever had to deal with long-lasting illnesses knows how much it impacts their ...

For the growing number of children with type 1 diabetes, the daily burden of managing their challenging chronic disease and ...

Ozempic, a popular medication for type 2 diabetes and weight management, is set to debut in India soon. Known for helping ...